117 related articles for article (PubMed ID: 24802657)
1. Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-γ agonist, after a single oral administration in healthy female subjects.
Park MK; Kim TE; Kim J; Kim C; Yoon SH; Cho JY; Jang IJ; Yu KS; Lim KS
Clin Drug Investig; 2014 Jul; 34(7):467-74. PubMed ID: 24802657
[TBL] [Abstract][Full Text] [Related]
2. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.
Kim JW; Kim JR; Yi S; Shin KH; Shin HS; Yoon SH; Cho JY; Kim DH; Shin SG; Jang IJ; Yu KS
Clin Ther; 2011 Nov; 33(11):1819-30. PubMed ID: 22047812
[TBL] [Abstract][Full Text] [Related]
3. No Relevant Pharmacokinetic Drug-Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects.
Kim YK; Hwang JG; Park MK
Drug Des Devel Ther; 2021; 15():1725-1734. PubMed ID: 33953542
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Interaction Between Amlodipine and Lobeglitazone, a Novel Peroxisome Proliferator-activated Receptor-γ Agonist, in Healthy Subjects.
Kim CO; Sil Oh E; Kim C; Park MS
Clin Ther; 2015 Sep; 37(9):1999-2006.e1. PubMed ID: 26163202
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects.
Shin D; Kim TE; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
Curr Med Res Opin; 2012 Jul; 28(7):1213-20. PubMed ID: 22697273
[TBL] [Abstract][Full Text] [Related]
6. Effect of ketoconazole on lobeglitazone pharmacokinetics in Korean volunteers.
Sil Oh E; Ok Kim C; Kim KH; Kim YN; Kim C; Lee JI; Park MS
Clin Ther; 2014 Jul; 36(7):1064-71. PubMed ID: 25047497
[TBL] [Abstract][Full Text] [Related]
7. Lack of the effect of lobeglitazone, a peroxisome proliferator-activated receptor-γ agonist, on the pharmacokinetics and pharmacodynamics of warfarin.
Jung JA; Lee SY; Kim TE; Kim JR; Kim C; Huh W; Ko JW
Drug Des Devel Ther; 2015; 9():737-43. PubMed ID: 25767371
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and bioequivalence of 0.5 mg lobeglitazone tablets in healthy male subjects
.
Lee SJ; Kim MG; Park SJ; Jeon JY
Int J Clin Pharmacol Ther; 2018 Sep; 56(9):426-433. PubMed ID: 29932413
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Pharmacokinetic Interaction Between Lobeglitazone and Dapagliflozin at Steady State.
Jang K; Jeon JY; Moon SJ; Kim MG
Clin Ther; 2020 Feb; 42(2):295-304. PubMed ID: 31992459
[TBL] [Abstract][Full Text] [Related]
10. An Assessment of Pharmacokinetic Interaction Between Lobeglitazone and Sitagliptin After Multiple Oral Administrations in Healthy Men.
Moon SJ; Yu KS; Kim MG
Clin Ther; 2020 Jun; 42(6):1047-1057. PubMed ID: 32362346
[TBL] [Abstract][Full Text] [Related]
11. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone.
Park J; Kim CO; Oh ES; Lee JI; Kim JK; Ahn SH; Kim DY; Kim SU; Kim BK; Chung YE; Kim SM; Park MS
Clin Pharmacol Drug Dev; 2022 May; 11(5):576-584. PubMed ID: 35255191
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a Lobeglitazone/Metformin Fixed-Dose Combination Tablet (CKD-395 0.5/1000 mg) Versus Concomitant Administration of Single Agents and the Effect of Food on the Metabolism of CKD-395 in Healthy Male Subjects.
Kim SY; Jeon JY; Park SJ; Kim MG
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):576-584. PubMed ID: 30329224
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial.
Kim SG; Kim DM; Woo JT; Jang HC; Chung CH; Ko KS; Park JH; Park YS; Kim SJ; Choi DS
PLoS One; 2014; 9(4):e92843. PubMed ID: 24736628
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPARα agonist with moderate PPARγ agonist activity in healthy human subjects.
Jani RH; Kansagra K; Jain MR; Patel H
Clin Drug Investig; 2013 Nov; 33(11):809-16. PubMed ID: 24062180
[TBL] [Abstract][Full Text] [Related]
15. A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial.
Baldoni D; Bruderer S; Krause A; Gutierrez M; Gueret P; Astruc B; Dingemanse J
Clin Drug Investig; 2014 Nov; 34(11):807-18. PubMed ID: 25331625
[TBL] [Abstract][Full Text] [Related]
16. Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial.
Schultze-Mosgau MH; Matsuki S; Okumura K; Kaneko M
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):49-56. PubMed ID: 34635989
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
18. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: a single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers.
Jung J; Choi S; Cho SH; Ghim JL; Hwang A; Kim U; Kim BS; Koguchi A; Miyoshi S; Okabe H; Bae KS; Lim HS
Clin Ther; 2010 Jun; 32(6):1178-87. PubMed ID: 20637970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
